HRP930083A2 - Veterinary-medical preparation, used as an additive to drinking water or to the animal food, containing the antibiotic mixture of gentamicin and lincomycin; its use in pig-breeding - Google Patents
Veterinary-medical preparation, used as an additive to drinking water or to the animal food, containing the antibiotic mixture of gentamicin and lincomycin; its use in pig-breeding Download PDFInfo
- Publication number
- HRP930083A2 HRP930083A2 HR930083A HRP930083A HRP930083A2 HR P930083 A2 HRP930083 A2 HR P930083A2 HR 930083 A HR930083 A HR 930083A HR P930083 A HRP930083 A HR P930083A HR P930083 A2 HRP930083 A2 HR P930083A2
- Authority
- HR
- Croatia
- Prior art keywords
- drinking water
- mass
- pigs
- lincomycin
- prophylaxis
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 48
- 241001465754 Metazoa Species 0.000 title claims description 38
- 239000003651 drinking water Substances 0.000 title claims description 27
- 235000020188 drinking water Nutrition 0.000 title claims description 27
- 230000003115 biocidal effect Effects 0.000 title claims description 18
- 239000000203 mixture Substances 0.000 title claims description 13
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 title claims description 11
- 229960005287 lincomycin Drugs 0.000 title claims description 11
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 title claims description 11
- 229960002518 gentamicin Drugs 0.000 title claims description 8
- 229930182566 Gentamicin Natural products 0.000 title claims description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 title claims description 7
- 239000000654 additive Substances 0.000 title claims description 4
- 230000000996 additive effect Effects 0.000 title claims description 4
- 235000013305 food Nutrition 0.000 title description 4
- 238000009395 breeding Methods 0.000 title description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 29
- 241000282887 Suidae Species 0.000 claims description 27
- 206010035664 Pneumonia Diseases 0.000 claims description 18
- 230000037396 body weight Effects 0.000 claims description 17
- 238000011321 prophylaxis Methods 0.000 claims description 16
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims description 10
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 claims description 10
- 229960001595 lincomycin hydrochloride Drugs 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 208000001848 dysentery Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 description 20
- 231100000517 death Toxicity 0.000 description 15
- 230000034994 death Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 10
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 229960000268 spectinomycin Drugs 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- ONXOKWFYBIQOFQ-VSXSCALHSA-N ac1l4s0d Chemical compound OS(O)(=O)=O.O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O.O[C@@H]1[C@H](O)[C@@H](O)[C@@H](SC)O[C@@H]1[C@@H]([C@@H](C)O)NC(=O)[C@H]1N(C)C[C@H](C(C)C)C1 ONXOKWFYBIQOFQ-VSXSCALHSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 210000002445 nipple Anatomy 0.000 description 6
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 229960004885 tiamulin Drugs 0.000 description 4
- 235000019733 Fish meal Nutrition 0.000 description 3
- 241000209219 Hordeum Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 235000019738 Limestone Nutrition 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 238000009313 farming Methods 0.000 description 3
- 239000004467 fishmeal Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006028 limestone Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XGBFWQUQYQIFLB-MTTMTQIXSA-N 23312-56-3 Chemical compound OS(O)(=O)=O.O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O XGBFWQUQYQIFLB-MTTMTQIXSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- YXQXDXAHCSEVSD-GCYNEOGWSA-N dynamutilin Chemical compound OC(=O)\C=C\C(O)=O.CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 YXQXDXAHCSEVSD-GCYNEOGWSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- DNYGXMICFMACRA-UHFFFAOYSA-N gentamicin C1A Natural products O1C(CNC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N DNYGXMICFMACRA-UHFFFAOYSA-N 0.000 description 2
- LKKVGKXCMYHKSL-LLZRLKDCSA-N gentamycin A Chemical compound O[C@H]1[C@H](NC)[C@@H](O)CO[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](N)C[C@H]1N LKKVGKXCMYHKSL-LLZRLKDCSA-N 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- -1 sulfate salt Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- CEAZRRDELHUEMR-CAMVTXANSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-CAMVTXANSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000791420 Plica Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000970875 Streptomyces spectabilis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 235000021052 average daily weight gain Nutrition 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical group [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930076781 gentamycin C1 Natural products 0.000 description 1
- VEGXETMJINRLTH-BOZYPMBZSA-N gentamycin C1a Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N VEGXETMJINRLTH-BOZYPMBZSA-N 0.000 description 1
- XUFIWSHGXVLULG-JYDJLPLMSA-N gentamycin C2 Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N XUFIWSHGXVLULG-JYDJLPLMSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Oblast tehnike u koju spada izum The technical field to which the invention belongs
Predmet izuma spada u oblast veterine, a naročito u oblast ishrane životinja. The subject of the invention belongs to the field of veterinary medicine, and especially to the field of animal nutrition.
Prema Međunarodnoj klasifikaciji predmeta (MKP) predmet izuma je razvrstan, odnosno klasificiran i označen klasificiran simbolom A23K 1/17 kojim je definirana stočna hrana s antibioticima. According to the International Classification of Objects (ICC), the subject of the invention is classified, i.e. classified and marked with the symbol A23K 1/17, which defines animal feed with antibiotics.
Ovaj izum predstavlja dopunski izum slovenskoj prijavi P-9200002 te se odnosi na veterinarsko-medicinski preparat kao dodatak pitkoj vodi ili životinjskoj hrani, koja sadržava antibiotičku mješavinu gentamicina i linkomicina, koji mogu biti u obliku slobodnih baza ili kiselinskih adicijskih soli, kao gentamicin sulfat i linkomicin hidroklorid, kao i za upotrebu u svrhu profilakse, te terapiju dizenterije i kolibaciloze te profilaksu enzootske pneumonije svinja, te pojedinačno za povećanje prirasta njihove tjelesne mase, smanjenju gubitaka te smanjenju broja oronulih životinja. This invention is a supplementary invention to the Slovenian application P-9200002 and relates to a veterinary medicinal preparation as an additive to drinking water or animal feed, which contains an antibiotic mixture of gentamicin and lincomycin, which can be in the form of free bases or acid addition salts, as gentamicin sulfate and lincomycin hydrochloride, as well as for use for the purpose of prophylaxis, and treatment of dysentery and colibacillosis and prophylaxis of enzootic pneumonia of pigs, and individually for increasing their body weight gain, reducing losses and reducing the number of decrepit animals.
Tehnički problem Technical problem
U intenzivnom svinjogojstvu najveće gubitke kod praščića udaljenih od sise (“Weanling pigs”) prouzrokuju gastrointestinalna i pneumonička oboljenja, te radi toga postoji stalna potreba za učinkovitu profilaksu i terapiju tih infekcija s djelotvornim antibioticima, odnosno kombinacijama antibiotika, kao dodatka pitkoj vodi ili životinjskoj hrani, čime bi posljedično povećali prirast tjelesne mase te smanjili uginuća prasadi. In intensive pig farming, the greatest losses in weanling pigs are caused by gastrointestinal and pneumonic diseases, and for this reason there is a constant need for effective prophylaxis and therapy of these infections with effective antibiotics, or combinations of antibiotics, as an addition to drinking water or animal feed , which would consequently increase the increase in body weight and reduce the deaths of piglets.
Stanje tehnike State of the art
Iz literature je poznata upotreba različitih antibiotika i kombinacija antibiotika, koji se dodaju životinjskoj hrani ili pitkoj vodi, da sprečavaju te liječe infekcije životinja za tov, te istovremeno djeluju na prirast tjelesne mase. Linkomicin je poznat antibiotik, koji je bio opisan u američkom patentu br. 3086912, koji koči rast i razmnožavanje brojnih mikroorganizama, pogotovo grampozitivnih bakterija, kao što su vrste staphylococus, Streptococus, Clostridium, Bacillus anthracis i Corynebacterium i nekih gramnegativnih bakterija, kao što su Bordetella i Haemophilus, te nekih vrsta Nocardia i Actinomyces. Naročito učinkovito djeluje na Treponemo hyodysenteriae, Mycoplasmo hyopneumoniae i Mycoplasmo galliseticum. Na osjetljive mikroorganizme djeluje bakteriostatički, kod većih koncentracija (2 do 3 puta veće MIC) još i baktericidno. The use of various antibiotics and combinations of antibiotics, which are added to animal feed or drinking water, is known from the literature to prevent and treat infections in animals for fattening, and at the same time they have an effect on body weight gain. Lincomycin is a known antibiotic, which was described in US patent no. 3086912, which inhibits the growth and reproduction of numerous microorganisms, especially gram-positive bacteria, such as species of staphylococus, Streptococus, Clostridium, Bacillus anthracis and Corynebacterium and some gram-negative bacteria, such as Bordetella and Haemophilus, and some species of Nocardia and Actinomyces. It is particularly effective against Treponemo hyodysenteriae, Mycoplasmo hyopneumoniae and Mycoplasmo galliseticum. It has a bacteriostatic effect on sensitive microorganisms, and at higher concentrations (2 to 3 times higher MIC) it is also bactericidal.
U američkom patentu br. 3 155 580 su opisani galenski oblici na osnovu linkomicina, odnosno njegovih kiselinskih adicijskih soli, kao aktivnog ingredienta za liječenje infekcija uzrokovanih bakterijama, kod ljudi i životinja. Kod životinja za tov može se antibiotik upotrijebiti profilaktički odnosno za prirast tjelesne mase. In US patent no. 3 155 580 described galenic forms based on lincomycin, i.e. its acid addition salts, as an active ingredient for the treatment of infections caused by bacteria, in humans and animals. In fattening animals, the antibiotic can be used prophylactically, i.e. to increase body weight.
Iz američkog patenta br. 3 150 042 poznata je upotreba linkomicina za profilaktičko i terapeutsko liječenje kokcidioze kod životinja, kod čega se upotrjebljava kao dodatak običnoj životinjskoj hrani ili primjerenoj količini pitke vode. Opisana je još upotreba tableta i sterilnih injekcijskih otopina. From US patent no. 3 150 042 the use of lincomycin for the prophylactic and therapeutic treatment of coccidiosis in animals is known, where it is used as an addition to ordinary animal feed or an adequate amount of drinking water. The use of tablets and sterile injection solutions is also described.
Gentamicin je antibiotik, koji je bio opisan u američkom patentu br. 3 091 572 i američkom patentu br. 3 136 704 te se sastoji od triju strukturno srodnih komponenata, gentamicina C1, C2 i C1a. Poznat je još Gentamicin A, koji se prema strukturi razlikuje od ostalih komponenti kompleksa. U galenskim oblicima nastupa gentamicin u obliku C kompleks sulfata (gentamicin sulfat). Gentamicin je vrlo učinkovit antibiotik protiv grampozitivnih i gramnegativnih mikroorganizama, kao što su vrste stafilococus, pneunomonas i proteus, te se upotrebljava kako u humanoj medicini tako i u veterini. Gentamicin is an antibiotic, which was described in US patent no. 3 091 572 and US patent no. 3 136 704 and consists of three structurally related components, gentamicin C1, C2 and C1a. Gentamicin A is also known, which is structurally different from the other components of the complex. In galenic forms, gentamicin appears in the C complex sulfate form (gentamicin sulfate). Gentamicin is a very effective antibiotic against gram-positive and gram-negative microorganisms, such as staphylococcus, pneumomonas and proteus species, and is used both in human medicine and in veterinary medicine.
Spektinomicin je antibiotik izoliran iz fermentacijske juhe Streptomyces spectabilis i bio je opisan u američkom patentu br. 3 234 094. Spektinomicin je aktivan protiv mycoplasmo, nekih grampozitivih i većinu gram negativnih bakterija, te se upotrebljava u veterini. U američkom patentu br. 3 245 797 opisana je životinjska hrana, koja sadržava spektinomicin u količini koja je učinkovita za podsticanje rasta tovljenika. Spectinomycin is an antibiotic isolated from the fermentation broth of Streptomyces spectabilis and was described in US patent no. 3 234 094. Spectinomycin is active against mycoplasmo, some gram-positive and most gram-negative bacteria, and is used in veterinary medicine. In US patent no. No. 3,245,797 describes an animal feed containing spectinomycin in an amount effective to promote growth in fattening animals.
U američkom patentu br. 3 261 687 opisana je životinjska hrana, koja sadrži kombinaciju antibiotika spektinomicina (u obliku sulfatne soli) i linkomicina (u obliku hidrokloridne soli) te postupak za povećanje prirasta tjelesne mase kod tovljenika, gdje je omjer antibiotika od 1 do 10 masenih dijelova spektinomicina i 1 maseni dio linkomicina, u sastavu životinjske hrane ili u pitkoj vodi. Oni navode, da su ovom kombinacijom antibiotika u životinjskoj hrani ili pitkoj vodi postigli neočekivano dobre rezultate u povećanju prirasta tjelesne mase i brzini kojom je ista rasla. Istovremeno kombinacija obiju antibiotika u životinjskoj hrani djeluje sinergistički, te je primjenjiva još za terapeutske i profilaktičko liječenje infekcija kod tovljenih životinja. In US patent no. 3 261 687 describes an animal feed containing a combination of the antibiotic spectinomycin (in the form of a sulfate salt) and lincomycin (in the form of a hydrochloride salt) and a procedure for increasing body weight gain in fattening animals, where the ratio of the antibiotic is from 1 to 10 parts by mass of spectinomycin and 1 the mass fraction of lincomycin, in the composition of animal feed or in drinking water. They state that with this combination of antibiotics in animal feed or drinking water, they achieved unexpectedly good results in increasing body weight gain and the speed with which it grew. At the same time, the combination of both antibiotics in animal feed acts synergistically, and is also applicable for therapeutic and prophylactic treatment of infections in fattened animals.
Nadalje je iz američkog patenta br. 3 679 787 poznata kombinacija linkomicina i spektinomicina u dozirnoj jedinici, u kombinaciji s nosiocima, te je prikladna za liječenje bolesti životinja, radi njihove sinergističke aktivnosti protiv infekcije mikroplazme. Furthermore, from US patent no. 3,679,787 known combination of lincomycin and spectinomycin in a dosage unit, in combination with carriers, and is suitable for the treatment of animal diseases, due to their synergistic activity against microplasma infection.
Tiamulin je polusintetički antibiotik širokog spektra, antimikrobnog djelovanja, koji je bio opisan u američkom patentu br. 3 919 290 te djeluje naročito na mikroplazme, kao i na mnogo grampozitivnih i gramnegativnih bakterija. U veterini se upotrebljava u profilaksi i kod terapije krvavih proljeva, kao i enzootske pneumonije kod svinja, kao i drugih infekcija prouzrokovanih preko mikroorganizama osjetljivih na tiamulin (u obliku respiratornih bolesti životinja, prouzročenih s mikroplazmama i sekundarnim infekcijama. Tiamulin is a semi-synthetic broad-spectrum, antimicrobial antibiotic, which was described in US patent no. 3 919 290 and acts especially on microplasmas, as well as on many gram-positive and gram-negative bacteria. In veterinary medicine, it is used in the prophylaxis and therapy of bloody diarrhea, as well as enzootic pneumonia in pigs, as well as other infections caused by microorganisms sensitive to tiamulin (in the form of respiratory diseases of animals, caused by microorganisms and secondary infections.
Opis rješenja tehničkog problema s primjerima Description of the solution to the technical problem with examples
Izum se zasniva na zadaći za pronalaženje učinkovitije kombinacije antibiotika u sastavu veterinarskomedicinskog preparata kao dodatka pitkoj vodi ili životinjskoj hrani, za primjenu u profilaksi i terapiji dizenterije te kolibacilozi i profilaksi enzootske pneumonije svinja te posljedično za povećanje prirasta njihove tjelesne mase, smanjenje gubitaka, kao i za smanjenje broja oronulih praščića i udjela uginuća istih. Rezultati što bi ih dobili takovom kombinacijom antibiotika u sastavu veterinarskomedicinskog preparata, kao dodatka pitkoj vodi ili životinjskoj hrani za svinje, nadmašili bi djelovanje pojedinih antibiotika ili poznatih kombinacija antibiotika za iste svrhe, što bi predstavljalo dragocjeno poboljšanje u svinjogojstvu. The invention is based on the task of finding a more effective combination of antibiotics in the composition of a veterinary medicinal preparation as an additive to drinking water or animal feed, for use in the prophylaxis and therapy of dysentery and colibacillosis and the prophylaxis of enzootic pneumonia in pigs, and consequently for increasing their body weight gain, reducing losses, as well as to reduce the number of dilapidated piglets and their mortality rate. The results that would be obtained with such a combination of antibiotics in the composition of a veterinary medicine, as an addition to drinking water or animal feed for pigs, would surpass the action of individual antibiotics or known combinations of antibiotics for the same purposes, which would represent a valuable improvement in pig farming.
U slovenskoj patentnoj prijavi P9200002 opisali smo životinjsku hranu i dodatak njoj ili pitkoj vodi kod uzgoja peradi, koja je sadržavala antibiotičku mješavinu 1 masenog dijela gentamicin sulfata i 5 do 60 masenih dijelova linkomicin hidroklorida za profilaksu i terapiju infekcija i posljedično za povećanje prirasta njihove tjelesne mase, kod čega smo povisili faktor uspješnosti na nisku konverziju hrane te smanjili ukupna uginuća. In the Slovenian patent application P9200002, we described an animal feed and addition to it or to drinking water for poultry farming, which contained an antibiotic mixture of 1 part by mass of gentamicin sulfate and 5 to 60 parts by mass of lincomycin hydrochloride for the prophylaxis and treatment of infections and consequently for increasing their body weight gain , where we increased the success factor to low food conversion and reduced total deaths.
U intenzivnoj svinjogojskoj proizvodnji prouzrokuju najveće gubitke kod praščića udaljenih od sise (“weanling pigs”), to jest nakon prestanka sisanja u vremenu od oko tri tjedna, gastrointestinalna i pneumonična oboljenja. Među uzročnicima gastrointestinalnih bolesti, primarno mjesto zauzima E.coli, koja prouzrokuje smetnje u intestinalnom traktu novorođenog praščića, kao i u starijoj dobi, naročito pak nakon udaljavanja od sise. E.coli je prirodni prebivalac digestivnog trakta, kao suprofit s mnogo drugih bakterija, kod čega u promijenjenim uvjetima u organizmu neki spojevi E.coli prouzrokuju bolest. In intensive pig production, gastrointestinal and pneumonic diseases cause the greatest losses in weanling pigs, that is, after the cessation of suckling for about three weeks. Among the causative agents of gastrointestinal diseases, the primary place is occupied by E.coli, which causes disturbances in the intestinal tract of newborn piglets, as well as in old age, especially after weaning. E.coli is a natural inhabitant of the digestive tract, as a co-profit with many other bacteria, where under changed conditions in the body, some compounds of E.coli cause disease.
Patološka stanja kod životinja izvzivaju samo varijante E.coli, koje su sposobne proizvoditi enterotoksine. Pod pojmom koliinfekcije praščića podrazumijevamo kompleks želučanocrijevnih oboljenjem diaroičnog značenja. Razlikujemo tri oblika bolesti, koje su vezane na starost praščića, naime kolidiareju novorođenčadi od sedmog dana starosti, kolibacilozu praščića koji još sišu, (10 dana starosti), te koligastroenteritis i kolienterotoksemiju od sise udaljenih praščića. Pathological conditions in animals are caused only by E.coli variants, which are capable of producing enterotoxins. By the term piglet coli infection, we mean a complex gastrointestinal disease with a diarrheic meaning. We distinguish between three forms of the disease, which are related to the age of the piglets, namely colidiarrhea of newborns from the seventh day of age, colibacillosis of piglets that are still suckling (10 days of age), and coligastroenteritis and colienterotoxemia from the teat of distant piglets.
Druga bolest, koja u intenzivnom svinjogojstvu prouzrokuje prilične direktne i indirektne gubitke (uginuća, odnosno uginuća od posljedica oronulosti svinja, kao posljedica bolesti) je enzootska (mikroplazmotska) pneumonija. Primarni uzročnik ove bolesti je Mycoplasma hyopneummoniea. U pogoršanim mikroklimatskim uvjetima uz surađivanje nekih bakterija, prouzrokuje kroničnu bolest visokog morbiditeta (boležljivosti) i niskog letaliteta (uginuće). Kod praščića starosti od 3 do 8 tjedana potječe bolest akutno, te može u slabim mikroklimatskim uvjetima letalitet biti veći od 10%. Uginuća nastupaju uglavnom radi sekundarnih bakterijskih infekcija. Svinja oboljela radi enzootske pneumonije ima slabiji prirast i manju konverziju. Another disease, which causes significant direct and indirect losses in intensive pig farming (deaths or deaths due to decrepitude of pigs as a result of the disease) is enzootic (microplasmotic) pneumonia. The primary causative agent of this disease is Mycoplasma hyopneummoniea. In deteriorated microclimatic conditions with the cooperation of some bacteria, it causes a chronic disease with high morbidity (sickness) and low lethality (death). In piglets aged 3 to 8 weeks, the disease starts acutely, and in poor microclimatic conditions, the lethality can be higher than 10%. Deaths occur mainly due to secondary bacterial infections. Pigs affected by enzootic pneumonia have lower growth and lower conversion.
U našim istraživanjima o mogućnostima sprječavanja koliinfekcija i enzootske pneumonije od sise udaljenih praščića, sa iznenađenjem smo ustanovili, da uz dodavanje novog preparata pitkoj vodi ili uobičajenoj hrani za svinje, u smislu izuma, postižemo željenu svrhu, koja u pogledu profilaktičkih, odnosno terapeutskih osobina nadmašuje u učinkovitosti poznate komercijalne preparate za istu svrhu. In our research on the possibilities of preventing coliinfections and enzootic pneumonia from the teats of distant piglets, we were surprised to find that by adding a new preparation to the drinking water or usual feed for pigs, in terms of the invention, we achieve the desired purpose, which in terms of prophylactic and therapeutic properties surpasses in the effectiveness of known commercial preparations for the same purpose.
Preparat u smislu izuma sadrži linkomicin i gentamicin, može u obliku slobodnih baza, ipak bolje u obliku njihovih farmaceutski prihvatljivih kiselininskih adicionih soli, kao linkomicin hidroklorid i gentamicin sulfat, u masenim dijelovima 1:1 do 1:10, pored uobičajene vodotopive podloge. Najbolje rezultate smo postigli s masenim omjerima linkocin hidroklorid i gentamicin sulfata od 1:1 do 1:3. Preparat u smislu izuma možemo davati u pitkoj vodi ili u životinjskoj hrani. Preparat dajemo praščićima od prvog dana udaljavanja od sise. Preparat u smislu izuma ispitivali smo uspoređujući klinički kod svinja obzirom na komercijalni preparat Linco-Spectin 44 premix, koji sadrži jednake udjele linkomicin hidroklorida i spektinomicin sulfata te komercijalnog preparata Tiavet P 2% praška, koji sadrži tiamulin hidrogen fumarat, te ih možemo davati u pitku vodu ili hrani za svinje u skladu s preporukama proizvođača. The preparation according to the invention contains lincomycin and gentamicin, it can be in the form of free bases, but better in the form of their pharmaceutically acceptable acid addition salts, such as lincomycin hydrochloride and gentamicin sulfate, in parts by weight of 1:1 to 1:10, in addition to the usual water-soluble base. We achieved the best results with mass ratios of lincocin hydrochloride and gentamicin sulfate from 1:1 to 1:3. The preparation according to the invention can be administered in drinking water or in animal feed. The preparation is given to piglets from the first day of weaning. We examined the preparation in terms of the invention by comparing it clinically in pigs with respect to the commercial preparation Linco-Spectin 44 premix, which contains equal parts of lincomycin hydrochloride and spectinomycin sulfate, and the commercial preparation Tiavet P 2% powder, which contains tiamulin hydrogen fumarate, and can be given in the drink. water or feed for pigs in accordance with the manufacturer's recommendations.
Dobiveni rezultati uspoređujućih kliničkih pokusa na svinjama, pokazali su, što je prikazano također u primjeru 1, da se kod primjene preparata u smislu izuma, obzirom na komercijalne preparate, snizuju ukupni gubici i uginuća s obilježjima proljeva i upale pluća za vrijeme uzgoja, snižava se postotak oronulih između kojih uopće nije bilo uginuća, pored toga je također konverzija (iskorištenje hrane) najniža uz primjenu preparata u smislu izuma, posljedično se pak poboljšava još i dnevni prirast tjelesne mase. The obtained results of the comparative clinical experiments on pigs showed, which is also shown in example 1, that with the application of the preparations according to the invention, compared to commercial preparations, total losses and deaths with symptoms of diarrhea and pneumonia during breeding are reduced. the percentage of decrepit among which there was no death at all, in addition, the conversion (use of food) is the lowest with the use of the preparation in terms of the invention, as a result, the daily increase in body weight also improves.
Na osnovu dobivenih rezultata možemo preparat u smislu izuma, upotrebljavati za profilaksu i terapiju dizenterije te kolibaciloze te za profilaksu enzootske penumonije svinja i pojedinačno za povećanje prirasta njihove tjelesne mase. Based on the obtained results, we can use the preparation in terms of the invention for the prophylaxis and therapy of dysentery and colibacillosis, as well as for the prophylaxis of enzootic pneumonia in pigs and individually for increasing their body weight.
Kombinaciju obiju antibiotika u smislu izuma, dodaje se u pitku vodu u koncentraciji od 1 mg/ml do 200 mg/ml pitke vode, ipak najbolje rezultate dobijemo u koncentraciji obiju antibiotika od oko 50 mg/ml pitke vode. The combination of both antibiotics in terms of the invention is added to drinking water in a concentration of 1 mg/ml to 200 mg/ml of drinking water, however, the best results are obtained in a concentration of both antibiotics of about 50 mg/ml of drinking water.
Kombinaciji obiju antibiotika kao dodatka životinjskoj hrani za svinje, dodajemo u ukupnoj koncentraciji od 0,5 kg/t do 5 kg/t, najbolje oko 1,5 kg/t čvrste hrane. We add the combination of both antibiotics as a supplement to animal feed for pigs in a total concentration of 0.5 kg/t to 5 kg/t, preferably around 1.5 kg/t of solid feed.
Izum objašnjavaju, ali ipak ne ograničavaju slijedeća dva primjera: The invention is explained, but not limited, by the following two examples:
Primjer 1 Example 1
Uspoređujući kliničko ispitivanje kombinacije antibiotika u smislu izuma (linkomicin-gentamicin), kombinacije linkomicina - spektinomicin i tiamulin kod svinja. Comparing the clinical trial of the antibiotic combination of the invention (lincomycin-gentamicin), the combination of lincomycin-spectinomycin and tiamulin in pigs.
Izveli smo uspoređujuće testiranje navedenih antibiotika odnosno kombinacije antibiotika s kojima smo željeli klinički ispitati učinkovitost kombinacije antibiotika u smislu izuma, za sprečavanje kolibaciloze i enzootske pneumonije svinja i posljedično ustanoviti prirast tjelesne mase. We carried out comparative testing of the mentioned antibiotics, that is, the combination of antibiotics with which we wanted to clinically test the effectiveness of the combination of antibiotics in the sense of the invention, to prevent colibacillosis and enzootic pneumonia of pigs and, consequently, determine the increase in body weight.
Kombinaciju antibiotika u smislu izuma, priredili smo u obliku praškastog preparata, koji ima slijedeće sastojke: We prepared the combination of antibiotics in terms of the invention in the form of a powder preparation, which has the following ingredients:
linkomicin hidroklorid 1,5 g lincomycin hydrochloride 1.5 g
gentamicin sulfat 4,0 g gentamicin sulfate 4.0 g
polietilenglikol 4000 prah 2,0 g polyethylene glycol 4000 powder 2.0 g
laktoza 42,5 g lactose 42.5 g
50,0 g 50.0 g
Preparat se priprema miješanjem sitnozrnatih tvrdih sastojaka u miješalici, kojeg zatim možemo dodati u pitku vodu ili životinjsku hranu. The preparation is prepared by mixing fine-grained hard ingredients in a mixer, which can then be added to drinking water or animal feed.
Kombinaciju antibiotika linkomicin-spektinomicin smo aplicirali u obliku komercijalnog preparata Linco-Spectin R44 premix (firma Upjohn Comp. USA) koji sadržava linkomicin hidroklorid i spektinomicin sulfat u omjeru 1:1, tiamulin pak aplicirali smo u obliku komercijalnog preparata Tiavet P 2% praška (firma Plica HR), koji sadrži tiamulin hidrogen fumarat. We applied the antibiotic combination lincomycin-spectinomycin in the form of the commercial preparation Linco-Spectin R44 premix (Upjohn Comp. USA), which contains lincomycin hydrochloride and spectinomycin sulfate in a ratio of 1:1, while we applied tiamulin in the form of the commercial preparation Tiavet P 2% powder ( company Plica HR), which contains tiamulin hydrogen fumarate.
U kliničkom ispitivanju preparata u smislu izuma uključili smo tri skupine od sise udaljenih praščića: In the clinical trial of the preparation in terms of the invention, we included three groups from the teats of remote piglets:
- skupina 1620 praščića udaljenih od sise dobivala je preparat u smislu izuma - a group of 1620 weaned piglets received the preparation according to the invention
- skupina 1687 praščića udaljenih od sise dobivala je preparat Linco-Spectin 44 premix - a group of 1687 weaned piglets received the preparation Linco-Spectin 44 premix
- skupina 1602 praščića udaljenih od sise dobivala je preparat Piavet P 2% prašak - a group of 1602 weaned piglets received the preparation Piavet P 2% powder
Praščići svih triju skupina, bili su jednakog genetskog porijekla. The piglets of all three groups were of the same genetic origin.
Preparat u smislu izuma aplicirali smo u vodu za piće u dozi 50 g na 100 litara od prvog do 21 dana nakon udaljavanja od sise. Kod životinja, koje su dobivale u vodi za piće preparat u smislu izuma, nismo primijetili nikakvih nuspojava. The preparation according to the invention was applied in drinking water at a dose of 50 g per 100 liters from the first to 21 days after weaning. We did not notice any side effects in the animals that received the preparation according to the invention in their drinking water.
Prije useljavanja pokusnih životinja, objekt smo oprali vrućom vodom pod pritiskom, te raskužili s preparatom VirkonR (Krka, SLO) koji je izbalansirana i stabilizirana smjesa peroksidnih spojeva, površinskih aktivnih tvari, organskih kiselina i organskog puferskog sistema. Before moving in the experimental animals, we washed the object with hot water under pressure, and disinfected it with the preparation VirkonR (Krka, SLO), which is a balanced and stabilized mixture of peroxide compounds, surfactants, organic acids and an organic buffer system.
Glavni sastojak je kalijev perkoksidsulfat (50%). Odmah nakon useljavanja praščići su dobili u vodi za piće vitaminski preparat BCK-forte+E prašak (firme Alkaloid, Skopje) koji sadrži vitamine A, B, E, C, B1, B2, B6 i B12 u dozi 200 g na 100 litara vode u 2 dana. The main ingredient is potassium peroxysulfate (50%). Immediately after moving in, the piglets received the vitamin preparation BCK-forte+E powder (Alkaloid, Skopje) in their drinking water, which contains vitamins A, B, E, C, B1, B2, B6 and B12 in a dose of 200 g per 100 liters of water in 2 days.
Od prvog do 21 dana nakon udaljavanja od sise, praščići su dobivali u vodi za piće preparat u smislu izuma u dozi 50 g na 100 litara vode. From the first to 21 days after weaning, the piglets received the preparation according to the invention in their drinking water at a dose of 50 g per 100 liters of water.
Kod praščića u testiranju, dnevno smo pratili pojave proljeva i pneumonije te uginuća. Praščiće smo izvagali prilikom udaljavanja od sise i kod useljenja u tovilište (tabele 2 i 3). In the piglets being tested, we monitored daily occurrences of diarrhea and pneumonia as well as deaths. We weighed the piglets when they were removed from the teat and when they moved into the feedlot (tables 2 and 3).
Rezultati testova nakon upotrebe preparata u smislu izuma, prikazani su u tabelama 2, 3, 4 i 5. The results of the tests after using the preparations according to the invention are shown in tables 2, 3, 4 and 5.
Za vrijeme kliničkog testiranja preparata u smislu izuma, odvojili smo 26 praščića (1,6%) koji su zaostali u prirastu tjelesne mase, u dva odvojena boksa. Do preseljenja u tovilište nijedno od spomenutih praščića nije uginulo. During the clinical testing of the preparation in terms of the invention, we separated 26 piglets (1.6%) that were lagging behind in body weight gain, into two separate pens. None of the mentioned piglets died until they were moved to the feedlot.
Za vrijeme uzgoja je uginulo 3,45% praščića sa znakovima proljeva i 1,3% praščića sa znakovima pneumonije (tabela 3). During breeding, 3.45% of piglets with signs of diarrhea and 1.3% of piglets with signs of pneumonia died (table 3).
Komparativno ispitivanje Comparative examination
Usporedno smo testirali dvije skupine svinja s jednakom starosnom dobi u jednakim hljevovima. We tested two groups of pigs of the same age in the same barns.
Prije useljenja praščića, oprali smo objekte vrućom vodom te ih raskužili preparatom VirkonR(Krka, SLO). Before the pigs moved in, we washed the facilities with hot water and disinfected them with VirkonR (Krka, SLO).
U prvoj pokusnoj skupini bilo je 1687 od sise udaljenih praščića koji su u hrani dobivali proizvod Linco-Spectin 44 u skladu s uputama proizvođača, u dozi 1 kg na tonu hrane u 3 tjedna. Praščići su počeli dobivati lijek 8 dana nakon udaljavanja od sise. In the first experimental group, there were 1,687 weaned piglets that received the product Linco-Spectin 44 in the feed in accordance with the manufacturer's instructions, at a dose of 1 kg per ton of feed for 3 weeks. Piglets started receiving the drug 8 days after weaning.
Druga usporedna skupina je brojila 1602 od sise udaljenih praščića, te je u hrani dobivala preparat Tiavet P 2% prašak u skladu s uputama proizvođača, u dozi 1,25 g na tonu hrane u 21 dan (tabela 1). Također i ova skupina je počela dobivati preparat od 8. dana udaljavanja od sise. The second comparison group consisted of 1,602 piglets removed from the teat, and received the preparation Tiavet P 2% powder in the feed in accordance with the manufacturer's instructions, at a dose of 1.25 g per ton of feed in 21 days (table 1). Also, this group started receiving the preparation from the 8th day of weaning.
Praščići u usporednom testiranju su pored spomenutih antibiotika u hrani 2 dana dobivali vitaminski preparat BCK-forte+E u vodi za piće, u dozi 200 g na 100 litara vode. Piglets in comparative testing were given the vitamin preparation BCK-forte+E in drinking water for 2 days in addition to the antibiotics mentioned in the feed, at a dose of 200 g per 100 liters of water.
Kod životinja u usporednom testiranju, dnevno smo pratili pojave proljeva i pneumonije te uginuća. In the animals in the comparative testing, we monitored daily occurrences of diarrhea and pneumonia as well as deaths.
Praščiće smo vagali kod udaljavanja od sise i prilikom preseljavanja u tovilište (tabela 2 i 3). We weighed the piglets when they were removed from the teat and when they were moved to the feedlot (tables 2 and 3).
Za vrijeme kliničkog testiranja u skupini koja je dobivala Linco-Spectin 44 odvojili smo 89 oronulih praščića (5,28%), kod skupine koja je dobivala Tiavet P 2% odvojili smo 112 praščića, koji su zaostali u prirastu tjelesne mase (6,9%). U prvoj skupini je od ovih uginulo 27 praščića (30,3%) a u drugoj skupini 38 praščića (33,9%). During the clinical testing in the group receiving Linco-Spectin 44 we separated 89 decrepit piglets (5.28%), in the group receiving Tiavet P 2% we separated 112 piglets, which lagged behind in body weight gain (6.9 %). Of these, 27 piglets (30.3%) died in the first group, and 38 piglets (33.9%) in the second group.
Tablica 1.: Broj životinja prema skupinama, proizvod i doziranje Table 1.: Number of animals according to groups, product and dosage
[image] [image]
Tablica 2: Prosječna tjelesna masa praščića prilikom udaljavanja od sise te preseljenja u tovilište i prosječni dnevni prirast tjelesne mase Table 2: Average body weight of piglets when weaned and moved to the feedlot and average daily weight gain
[image] [image]
Tabela 2 pokazuje, da je skupina praščića, koja je dobivala u vodi za piće preparat u smislu izuma, kod preseljenja u tovilište postigla najveću prosječnu tjelesnu masu te najveći dnevni prirast. Table 2 shows that the group of piglets, which received the preparation according to the invention in their drinking water, achieved the highest average body weight and the highest daily growth when moving to the feedlot.
Tablica 3: Ukupni gubici i uginuća sa znakovima proljeva ili upale pluća te konverzija hrane za vrijeme uzgoja Table 3: Total losses and deaths with signs of diarrhea or pneumonia and feed conversion during rearing
[image] [image]
Tabela 3 prikazuje, da su kod skupine, koja je dobivala preparat u smislu izuma, ukupni gubici i uginuća sa znakovima proljeva i upale pluća za vrijeme uzgoja u usporedbi sa skupinama u usporednom testiranju najniži. Table 3 shows that in the group that received the preparation according to the invention, the total losses and deaths with signs of diarrhea and pneumonia during cultivation were the lowest in comparison with the groups in comparative testing.
Konverzija je najniža u skupini, koja je dobivala preparat u smislu izuma. Conversion is the lowest in the group that received the preparation according to the invention.
Tablica 4: Broj oronulih praščića i udio uginuća od istih Table 4: Number of dilapidated piglets and proportion of deaths from them
[image] [image]
Tablica 4 prikazuje, da je najniži postotak oronulih praščića u skupini, koja je dobivala preparat u smislu izuma i da u toj skupini nije uginuo nijedan od oronulih, a u poredbenoj skupini više od 30%. Table 4 shows that the lowest percentage of decrepit piglets was in the group that received the preparation according to the invention and that none of the decrepit pigs died in that group, and more than 30% in the comparison group.
U tablici 5 su pregledno prikazani ukupni rezultati u svim skupinama, koji su dobivali preparat u smislu izuma, Linco-Spectin 44 premix i Tiavet P 2%. Table 5 shows the overall results in all groups, which received the preparation according to the invention, Linco-Spectin 44 premix and Tiavet P 2%.
Sažetak rezultata kliničkog testiranja preparata u smislu izuma: Summary of the results of clinical testing of the preparation in terms of the invention:
Kliničko ispitivanje preparata u smislu izuma kod praščića udaljenih od sise je pokazalo, da preparat nema popratne pojave. Clinical testing of the preparation according to the invention in weaned piglets showed that the preparation has no side effects.
Skupina od sise udaljenih praščića, koja je dobivala preparat u smislu izuma je pokazala poboljšane rezultate prema poredbenim skupinama, koje su primale komercijalne preparate Linco-Specti 44 premix i Tiavet P 2% u pogledu: The group of udders of remote piglets, which received the preparation according to the invention, showed improved results compared to the comparison groups, which received the commercial preparations Linco-Specti 44 premix and Tiavet P 2% in terms of:
- prosječnog dnevnog prirasta - average daily growth
- prosječnog iskorištenja hrane - average utilization of food
- postotak ukupnih gubitaka - percentage of total losses
- postotak uginulih sa znakovima upale pluća - percentage of those who died with signs of pneumonia
- postotak uginulih sa znakovima proljeva - percentage of deaths with signs of diarrhea
- postotak oronulih - percentage of dilapidated
- postotak uginuća oronulih. - the percentage of deaths of the decrepit.
Tablica 5: Table 5:
[image] [image]
Primjer 2 Example 2
Procentualni sastav životinjske hrane za svinje kojima dajemo kombinaciju antibiotika u smislu izuma, može biti sastavljena od slijedećih sastojaka: The percentage composition of animal feed for pigs to which we give the combination of antibiotics in terms of the invention can be composed of the following ingredients:
Predpočetak: Pre-start:
kukuruz 40,23% corn 40.23%
ječam 10,00% barley 10.00%
Pšenično brašno za krmivo 5,00% Wheat flour for feed 5.00%
sojin trop 16,20% soy trope 16.20%
Prelac Nutrifit F 2 EDR (mliječ. dodatak) 20,00% Prelac Nutrifit F 2 EDR (milk supplement) 20.00%
riblje brašno 2,00% fish meal 2.00%
šećer 3,00% sugar 3.00%
vapnenac 1,05% limestone 1.05%
ZoofosR (Ca, P) 0,32% ZoofosR (Ca, P) 0.32%
premix SP (vit.miner.) 1,00% premix SP (vit.miner.) 1.00%
metionin 0,03% methionine 0.03%
Početak: Beginning:
kukuruz 43,19% corn 43.19%
ječam 15,00% barley 15.00%
Pšenično brašno za krmivo 5,00% Wheat flour for feed 5.00%
sojin trop 16,18% soy trope 16.18%
Prelac Nutrifit F 2 ED 15,00% Prelac Nutrifit F 2 ED 15.00%
riblje brašno 2,00% fish meal 2.00%
vapnenac 0,93% limestone 0.93%
ZoofosR 1,33% ZoofosR 1.33%
premix SP 1,00% premix SP 1.00%
životinjska sol 0,35% animal salt 0.35%
Lizin 0,02% Lysine 0.02%
metionin 0,01% methionine 0.01%
Grower: Grower:
kukuruz 48,53% corn 48.53%
ječam 10,00% barley 10.00%
pšenica 10,00% wheat 10.00%
sojin trop 21,15% soy trope 21.15%
Prelac Nutrifit F 2 ED 4,00% Prelac Nutrifit F 2 ED 4.00%
riblje brašno 3,00% fish meal 3.00%
vapnenac 0,79% limestone 0.79%
Zoofos 1,20% Zoofos 1.20%
životinjska sol 0,42% animal salt 0.42%
Premix SP 0,80% Premix SP 0.80%
lizin 0,09% lysine 0.09%
metionin 0,02% methionine 0.02%
Predpočetak: 8 - 26 dan starosti Pre-start: 8 - 26 days of age
Početak: 26 - 47 dan starosti Start: 26 - 47 days of age
Grower: 47 – 80 dan starosti__ Grower: 47 – 80 days of age__
Claims (5)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI9200167A SI9200167B (en) | 1992-08-11 | 1992-08-11 | Veterinary preparation containing an antibiotic mixture of gentamycin and lincomycin as an additive to drinking water or animal feed and its use in pig breeding |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP930083A2 true HRP930083A2 (en) | 1994-08-31 |
Family
ID=20430981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR930083A HRP930083A2 (en) | 1992-08-11 | 1993-02-01 | Veterinary-medical preparation, used as an additive to drinking water or to the animal food, containing the antibiotic mixture of gentamicin and lincomycin; its use in pig-breeding |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR950009945B1 (en) |
HR (1) | HRP930083A2 (en) |
SI (1) | SI9200167B (en) |
YU (1) | YU493A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002090852A1 (en) | 2001-05-03 | 2002-11-14 | Dragutin Radovanovic | Device for fruit and vegetable drying in vacuum |
-
1992
- 1992-08-11 SI SI9200167A patent/SI9200167B/en unknown
-
1993
- 1993-01-06 YU YU493A patent/YU493A/en unknown
- 1993-02-01 HR HR930083A patent/HRP930083A2/en not_active Application Discontinuation
- 1993-02-20 KR KR1019930002400A patent/KR950009945B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
YU493A (en) | 1996-10-18 |
SI9200167A1 (en) | 1994-03-31 |
KR940003475A (en) | 1994-03-12 |
KR950009945B1 (en) | 1995-09-04 |
SI9200167B (en) | 1999-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cromwell | Antimicrobial and promicrobial agents | |
US9084432B2 (en) | Feeds containing hop acids and uses thereof as supplements in animal feeds | |
CN107484879A (en) | Feed addictive, antibiotic-free feed and its application | |
US4336250A (en) | Lactation improvement method | |
US4504471A (en) | Animal growth promotant and method of use for animal growth | |
EP0597167B1 (en) | Veterinary preparation containing an antibiotic mixture of gentamicin and lincomycin as an additive to drinking water or animal feed and its use in pig breeding | |
HRP930083A2 (en) | Veterinary-medical preparation, used as an additive to drinking water or to the animal food, containing the antibiotic mixture of gentamicin and lincomycin; its use in pig-breeding | |
US3577529A (en) | Compositions and methods for enhancement of the growth rate of poultry and animals employing alkali metal formaldehyde sulfoxylates and bisulfites | |
JPH06303918A (en) | Feed additive composition for swine and poultry | |
RU2831747C1 (en) | Method for increasing multiple pregnancy and heavy farrowing of pigs | |
ES2401877T3 (en) | Use of sulfadimidine amides for the treatment of intestinal diseases in veterinary science | |
Coates et al. | Vitamins in animal nutrition | |
JPH10165109A (en) | Feed composition and feed | |
JPH0291026A (en) | Method for preventing and treating liver tumor of animal and animal feed composition | |
AU623927B2 (en) | Synergistically active compositions and process for preparing the same | |
US5719121A (en) | Use of balhimycin as production promoter in animals, and production promoter compositions | |
JP2021193979A (en) | Livestock first milk quality improver and method | |
GB2158353A (en) | Veterinary preparations | |
HU201668B (en) | Method for producing veterinary preparation and fodder premixture of synergetic effect serving for making more economical breeding of animals | |
CS205734B1 (en) | Fodder admixture in the form of the probiotic premixe or supplement of the biofactor with the probiotic | |
HU217306B (en) | Feed additive composition | |
CS239619B1 (en) | Pharmaceutical agent for fodder for cattle with grow-stimulating effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODBC | Application rejected |